FDA's Drug Abuse Advisory Committee
This article was originally published in The Tan Sheet
Executive Summary
Will discuss "abuse liability assessment and related issues" regarding Kabi Pharmacia's NDA for a prescription nicotine nasal spray on the first day of an Aug. 1- 3 meeting. On Aug. 2, the committee will address issues related to nicotine and smoking, including the relationship between nicotine dose and addiction in smokers. The meeting will begin at 9 a.m. each day in the Plaza Ballroom of the Holiday Inn at 8777 Georgia Avenue, Silver Spring, Md
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning